Q3 EPS Estimate for Xenon Pharmaceuticals Lowered by Analyst

Key Points

• William Blair has revised its Q3 2025 earnings estimates for Xenon Pharmaceuticals, forecasting a loss of ($1.20) per share, down from a previous estimate of ($1.07).
• The company reported a Q2 loss of ($1.07) EPS, missing the consensus estimate by ($0.04), and has a current full-year earnings estimate of ($3.10) EPS.
• Xenon Pharmaceuticals has an average rating of "Moderate Buy" among analysts, with an average target price of $53.20.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at William Blair decreased their Q3 2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now expects that the biopharmaceutical company will post earnings per share of ($1.20) for the quarter, down from their prior estimate of ($1.07). William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. William Blair also issued estimates for Xenon Pharmaceuticals' Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($4.32) EPS, Q1 2026 earnings at ($0.96) EPS, Q2 2026 earnings at ($1.16) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.27) EPS and FY2026 earnings at ($4.59) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period last year, the company posted ($0.75) earnings per share.

A number of other brokerages have also recently issued reports on XENE. Wedbush upped their price target on shares of Xenon Pharmaceuticals from $42.00 to $43.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th. Needham & Company LLC lowered their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Wells Fargo & Company lowered their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their price target on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating on the stock in a report on Tuesday, August 12th. Finally, Wall Street Zen downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. One equities research analyst has rated the stock with a sell rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $53.20.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE traded up $0.27 during mid-day trading on Thursday, hitting $38.23. 820,100 shares of the stock traded hands, compared to its average volume of 1,051,328. Xenon Pharmaceuticals has a 52 week low of $26.74 and a 52 week high of $46.00. The company has a market cap of $2.95 billion, a price-to-earnings ratio of -10.77 and a beta of 1.16. The stock has a fifty day moving average price of $32.59 and a 200-day moving average price of $34.02.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC bought a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth approximately $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Xenon Pharmaceuticals during the 1st quarter worth $30,000. Elevation Point Wealth Partners LLC purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth $32,000. GF Fund Management CO. LTD. purchased a new position in Xenon Pharmaceuticals during the 4th quarter worth $63,000. Finally, Quarry LP purchased a new position in Xenon Pharmaceuticals during the 4th quarter worth $78,000. Hedge funds and other institutional investors own 95.45% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.